Bioequivalence Study of Simvastatin 40 mg Film-coated Tablets in Healthy Thai Volunteers

NCT ID: NCT06178640

Last Updated: 2024-03-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 46 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-13
• Study Completion Date: 2024-08-24

Brief Summary

The goal of this bioequivalence study is to determine and compare the rate and extent of absorption and to evaluate safety of test and reference formulations. Study Design: An open label, randomized, two-treatment, four-period, two-sequence replicate crossover bioequivalence study in 46 healthy Thai volunteers under fasting conditions with at least 7 days washout period.

Detailed Description

The primary objective of this bioequivalence study is to assess and compare the rate and extent of absorption of a test formulation against a reference formulation, with an additional focus on evaluating the safety profiles of both formulations. This study aims to provide critical insights into the bioequivalence of the two formulations, shedding light on their pharmacokinetic parameters and overall safety in the context of therapeutic efficacy.

Study Design:

The study adopts an open-label, randomized, two-treatment, four-period, two-sequence replicate crossover design to ensure robustness and reliability in the evaluation of bioequivalence. The crossover design minimizes the impact of inter-individual variability, allowing for a more accurate assessment of the formulations' performance.

Participant Selection:

A total of 46 healthy Thai volunteers will be recruited to participate in the study. The inclusion criteria involve individuals who meet specific health standards and are willing to comply with the study requirements. The emphasis on recruiting healthy volunteers aims to establish a baseline for comparison, ensuring that any observed differences in absorption and safety can be attributed to the formulations under investigation.

Study Conditions:

The study will be conducted under fasting conditions to isolate the impact of the formulations on absorption without interference from food-related variables. Fasting conditions provide a controlled environment to evaluate the formulations' performance and allow for a more accurate determination of bioequivalence.

Conditions

Healthy Volunteer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Simvastatin 40 mg, Then ZOCOR 40 mg

Participants first received Simvastatin 40 mg film-coated tablet 1 tablet (Test product) in a fasting state. After a washout period of 1 week, they then recieved ZOCOR 40 mg film-coated tablet (Reference product) in a fasting state

Group Type: EXPERIMENTAL

Simvastatin 40 mg film-coated tablet

Intervention Type: DRUG

Simvastatin 40 mg film-coated tablet

Zocor 40 mg film-coated tablet

Intervention Type: DRUG

Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)

ZOCOR 40 mg, Then Simvastatin 40 mg

Participants first received ZOCOR 40 mg film-coated tablet 1 tablet (Reference product) in a fasting state. After a washout period of 1 week, they then recieved Simvastatin 40 mg film-coated tablet (Test product) in a fasting state.

Group Type: ACTIVE_COMPARATOR

Simvastatin 40 mg film-coated tablet

Intervention Type: DRUG

Simvastatin 40 mg film-coated tablet

Zocor 40 mg film-coated tablet

Intervention Type: DRUG

Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)

Interventions

Simvastatin 40 mg film-coated tablet

Simvastatin 40 mg film-coated tablet

Intervention Type: DRUG

Zocor 40 mg film-coated tablet

Zocor 40 mg film-coated tablet (Simvastatin 40 mg film-coated tablet: Reference Product)

Intervention Type: DRUG

Other Intervention Names

Simvastatin; Simvastatin

Eligibility Criteria

Inclusion Criteria

1. Healthy Thai male or female subjects between the ages of 18 - 55 years

2. Body mass index between 18.5 - 30.0 kg/m2

3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study.

4. Non-pregnant woman (negative pregnancy test) and not currently breast feeding

5. Female subjects abstain from either hormonal method of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing Intrauterine Device (IUDs), postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera® will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies, or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 4. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1: Postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months.

6. Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 4.

7. Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study

Exclusion Criteria

1. History of allergic reaction or hypersensitivity to simvastatin or to any excipients of tablet

2. History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper-/hypothyroid, diabetes), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper-/hypotension), psychiatric (e.g. depression), neurologic (e.g. convulsant), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness

3. History or evidence of muscular disease e.g. muscle pain, tenderness, weakness, myopathy or rhabdomyolysis

4. Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of coronavirus disease starting in 2019 (COVID-19)

5. History about administration of COVID-19 vaccine within 30 days prior to check-in in each Period

6. History of problems with swallowing tablet or capsule

7. History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption

8. History of sensitivity to heparin or heparin-induced thrombocytopenia

9. Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy

10. History of diarrhea or vomiting within 24 hours prior to check-in in each period

11. 12-lead ECG demonstrating corrected QT interval (QTc) >450 msec, a QRS Complex (QRS interval) >120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subject's eligibility.

12. Investigation with blood sample shows positive test for HBsAg.

13. History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine)

14. History or evidence of liver disease or renal impairment

15. Creatine kinase (CK) levels > 1.5 times of upper normal limit of reference range (unless explained by exercise) at screening laboratory test.

16. Have epidermal growth factor receptor(eGFR) (CKD-EPI) <30 mL/min/1.73 m2 based on serum creatinine results, at the screening laboratory test or during enrollment

17. Abnormal liver function, ≥1.5 times of upper normal limit of reference range for Alanine Transaminase (ALT), Aspartate transaminase (AST) or bilirubin levels at screening laboratory test

18. History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study

19. History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.)

20. History or evidence of alcohol consumption or alcohol-containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study or alcohol breath test shows positive result. In case of alcohol breath test result represents the alcohol concentration range of 1 - 10 mg% Blood alcohol concentration (BAC) and the physician carefully considers that the value came from other reasons, not from the alcohol drinking behavior of subjects, the test will be repeated two times separately, not more than 10 minutes. The result of the last time should be used for subject's eligibility which must be 0 mg%BAC.

21. History or evidence of habitual consume of tea, coffee, xanthine or caffeine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study

22. History or evidence of strenuous exercise and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study.

23. Consume or drink juice of grapefruit or orange or pomelo or its supplement/containing products and cannot abstain for at least 7 days prior to check-in in Period 1 and continued for entire duration of the study

24. Use of prescription or nonprescription drugs (e.g. paracetamol, potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, erythromycin, clarithromycin), HIV protease inhibitors (e.g. nelfinavir), cyclosporine, statins, fibrates, gemfibrozil, daptomycin, niacin, fusidic acid etc.), herbal medications or supplements (e.g. St. John's wort), vitamins or mineral (e.g. iron) or dietary supplements within 14 days prior to check-in in Period 1 and continued for entire duration of the study

25. Participated in other clinical trials within 90 days prior to check-in in Period 1 (except for the subjects who drop out or withdrawn from the previous study prior to Period 1 dosing) or still participates in the clinical trial or participates in other clinical trials during enrollment in this study

26. Blood donation or blood loss ≥ 1 unit (1 unit is equal to 350-450 mL of blood) within 90 days prior to check-in in Period 1 or during enrollment

27. Subjects with poor venous access or intolerant to venipuncture

28. Unwilling or unable to comply with schedule visit, treatment plan and other study procedures until end of study

29. Inability to communicate well (i.e. language problem, poor mental development, psychiatric illness or poor cerebral function) that may impair the ability to provide written informed consent or cooperate with clinical team

30. Subjects who are employees of International Bio Service Co., Ltd. or sponsor

31. Unwilling or unable to comply with schedule visit, treatment plan and other study procedures until end of study.

32. Inability to communicate well (i.e. language problem, poor mental development, psychiatric illness or poor cerebral function) that may impair the ability to provide written informed consent or cooperate with clinical team)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

International Bio service

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Uthai Suvanakoot, Ph.D.Pharm

Role: PRINCIPAL_INVESTIGATOR

International Bio service

Central Contacts

Nannapat Wannaphruek, Pharm.D.

Role: CONTACT

nannapat.wan@mahidol.ac.th

024415211

Thanaporn Wongyai, B.Sc.Pharm

Role: CONTACT

thanaporn.won@mahidol.ac.th

024415211

Other Identifiers

BE23-041

Identifier Type: -

Identifier Source: org_study_id